Claims
- 1. A pure PS/A comprising the following structure:
- 2. The PS/A of claim 1, wherein at least 80% of the R groups are —NH—CO—CH3.
- 3. The PS/A of claim 1, wherein n is an integer of greater than or equal to 490.
- 4. The PS/A of claim 1, wherein the PS/A has a molecular weight of greater than 200,000.
- 5. The PS/A of claim 1, wherein the PS/A has a molecular weight of greater than 250,000.
- 6. The PS/A of claim 1, wherein the PS/A is a homo-substituted polymer.
- 7. The PS/A of claim 1, wherein the PS/A is a hetero-substituted polymer.
- 8. The PS/A of claim 1, wherein the PS/A is formulated as a vaccine.
- 9. The PS/A of claim 1, further comprising at least one carrier compound conjugated to the PS/A.
- 10. The PS/A of claim 9, wherein the carrier compound is conjugated to the PS/A through a linker.
- 11. The PS/A of claim 9, wherein the carrier compound is a peptide carrier.
- 12. The PS/A of claim 1, wherein no carrier compound is present.
- 13. The PS/A of claim 1, wherein the PS/A is at least 95% pure.
- 14. The PS/A of claim 1, wherein the PS/A is at least 97% pure.
- 15. The PS/A of claim 1, wherein the PS/A has a molecular weight of between 150,000 and 5,000,000 Daltons.
- 16. The PS/A of claim 1, wherein the PS/A is substantially free of teichoic acid.
- 17. The PS/A of claim 1, wherein said PS/A consists of the following structure:
- 18. An isolated PS/A, comprising at least 300 monomeric units, at least 50% of which are substituted with acetate, the PS/A having a molecular weight of at least 100,000 Daltons, wherein at least 50% of the units are β-1,6-glucosamine units.
- 19. The PS/A of claim 18, wherein all of the units are β-1,6-glucosamine units.
- 20. The PS/A of claim 18, wherein the remaining units are selected from the group consisting of α-1-6 polyglucose, α-1-4 polyglucose, α-1-3 polyglucose, β-1-4 polyglucose, β-1-3 polyglucose, and α-1-4 polygalactose.
- 21. The PS/A of claim 18, wherein the PS/A has a polymer backbone in a β-1,6 formation.
- 22. The PS/A of claim 18, wherein the PS/A has a polymer backbone in a β-1,4 formation.
- 23. The PS/A of claim 18, wherein the PS/A has a polymer backbone in a α-1,3 formation.
- 24. The PS/A of claim 18, wherein at least 80% of the R groups are acetate.
- 25. A polysaccharide antigen comprising:
a PS/A prepared according to the following method: preparing an impure PS/A from a bacterial culture, incubating the impure PS/A with an acid or a base to produce a semi-pure PS/A preparation; neutralizing the preparation, and incubating the neutralized preparation in hydrofluoric acid to produce the PS/A.
- 26. The antigen of claim 25, wherein the bacterial culture is a Staphylococcus aureus culture.
- 27. The antigen of claim 25, wherein the bacterial culture is a coagulase negative Staphylococci culture.
- 28. The antigen of claim 25, wherein the molecular weight is between 100,000 and 5,000,000 Daltons.
- 29. The antigen of claim 25, formulated as a vaccine.
- 30. The antigen of claim 25, further comprising at least one carrier compound conjugated to the PS/A.
- 31. The antigen of claim 30, wherein the carrier compound is conjugated to the PS/A through a linker.
- 32. The antigen of claim 30, wherein the carrier compound is a peptide carrier.
- 33. The antigen of claim 30, wherein no carrier compound is present.
- 34. The antigen of claim 25, wherein the PS/A is at least 95% pure.
- 35. A composition comprising the PS/A of any one of claims 1, 18, and 25 and a pharmaceutically acceptable carrier.
- 36. A PS/A comprising the following structure:
- 37. The PS/A of claim 36, wherein at least 80% of said R groups are —NH—CO—CH3.
- 38. The PS/A of claim 36, wherein each of said R groups is —NH—CO—CH3.
- 39. The PS/A of claim 36, wherein X is a carrier molecule and wherein the carrier molecule is a polysaccharide, provided that X may be optionally substituted directly, or through a linker, with one or more carrier peptides.
- 40. The PS/A of claim 36, wherein X is a carrier peptide.
- 41. The PS/A of claim 36, wherein Y is a carrier molecule and wherein the carrier molecule is a polysaccharide, provided that Y may be optionally substituted directly, or through a linker, with one or more carrier peptides.
- 42. The PS/A of claim 36, wherein Y is a carrier peptide.
- 43. The PS/A of claim 36, wherein the PS/A has a molecular weight of between 100,000 and 5,000,000 Daltons
- 44. A method of preparing a polysaccharide antigen comprising:
preparing an impure PS/A from a bacterial culture, incubating the impure PS/A with a base or acid to produce a semi-pure PS/A preparation; neutralizing the preparation, and treating the neutralized preparation to produce the PS/A.
- 45. A method for preventing infection by staphylococcus in a subject comprising:
administering to a non-rodent subject an effective amount for inducing an immune response against staphylococcus of an PS/A of any one of claims 1-43.
- 46. The method of claim 45, wherein the staphylococcus is staphylococcus aureus.
- 47. The method of claim 45, wherein the staphylococcus is staphylococcus epidermidis.
- 48. The method of claim 45, wherein the non-rodent subject is a human subject.
- 49. The method of claim 45, wherein the non-rodent subject is selected from the group consisting of primates, horses, cows, swine, goats, sheep, chicken, dogs, and cats.
- 50. The method of claim 45, wherein the non-rodent subject is a subject at risk of exposure to staphylococcus.
- 51. The method of claim 45, wherein the non-rodent subject is a subject which has been exposed to staphylococcus.
- 52. The method of claim 45, wherein the PS/A is administered in conjunction with an adjuvant.
- 53. A method for preventing infection by staphylococcus in a subject comprising:
administering to a non-rodent subject an effective amount for inducing an immune response against staphylococcus of a pure capsular polysaccharide antigen having the following structure: 14wherein n is at least 3, wherein R is selected from the group consisting of —NH—CO—(CH2) m—COOH, —NH—CO—CH3, and —NH2, wherein m is 1-5, provided that at least 50% of the R groups are —NH—CO—CH3, wherein the subject has not received a medical device implant.
- 54. A method for preventing infection by staphylococcus in a subject comprising:
systemically administering to a non-rodent subject an effective amount for inducing an immune response against staphylococcus of a pure capsular polysaccharide antigen having the following structure: 15wherein n is at least 3, wherein R is selected from the group consisting of —NH—CO—(CH2) m—COOH, —NH—CO—CH3, and —NH2, wherein m is 1-5, provided that at least 50% of the R groups are —NH—CO—CH3.
- 55. The method of any one of claims 52 or 53, wherein the antigen is administered in conjunction with an adjuvant.
- 56. The method of any one of claims 52 or 53, wherein the antigen is conjugated to a carrier compound.
- 57. The method of claim 55, wherein the carrier compound is a peptide carrier.
- 58. A method for generating antibodies comprising:
administering to a subject an effective amount for producing antibodies specific for staphylococcus of an PS/A of any one of claims 1-43 and an adjuvant, and isolating antibodies from the subject.
- 59. The method of claim 53, further comprising manipulating the antibodies to generate monoclonal antibodies.
- 60. A method of identifying a monoclonal antibody against a PS/A, comprising:
inducing an immune response in a non-human subject to the PS/A, isolating antibody producing cells from said subject, producing immortalized cells from said antibody producing cells, testing the ability of said immortalized cells to produce said monoclonal antibody using an PS/A of any one of claims 1-43.
- 61. The method of claim 59, further comprising making a monoclonal antibody by purifying said monoclonal antibody produced from said immortalized cells.
RELATED APPLICATIONS
[0001] This application is a continuation in part of U.S. Ser. No. 09/399,904 filed on Sep. 21, 1999 and entitled Polysaccharide Vaccine for Staphylococcal Infections, now pending, which is a continuation in part of U.S. Ser. No. 09/354,408 filed on Jul. 15, 1999 and entitled Polysaccharide Vaccine for Staphylococcal Infections, now pending, which claims priority to U.S. Provisional Patent Application No. 60/093,117, filed Jul. 15, 1998, the entire contents of which are hereby incorporated by reference.
GOVERNMENT SUPPORT
[0002] The present invention was supported in part by a grant from the United States National Institutes of Health AI23335. The U.S. Government may retain certain rights in the invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60093117 |
Jul 1998 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
09399904 |
Sep 1999 |
US |
Child |
09771003 |
Jan 2001 |
US |
Parent |
09354408 |
Jul 1999 |
US |
Child |
09399904 |
Sep 1999 |
US |